Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. (2017)

First Author: Taylor SJ
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aam8060

PubMed Identifier: 28794285

Publication URI: http://europepmc.org/abstract/MED/28794285

Type: Journal Article/Review

Volume: 9

Parent Publication: Science translational medicine

Issue: 402

ISSN: 1946-6234